
AVCTF
Healthcare · Biotechnology · $337.0M market cap
$0.77000.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.03 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.03 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.03 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.03 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Jul 31, 2019 | Time not confirmed | 0.00 | -0.02 | — |
| Apr 30, 2019 | Time not confirmed | 0.00 | -0.03 | — |
| Jul 31, 2018 | Time not confirmed | 0.00 | -0.05 | — |
| Apr 30, 2018 | Time not confirmed | 0.00 | -0.05 | — |
| Jan 31, 2018 | Time not confirmed | 0.00 | -0.04 | — |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent…